Tocilizumab co-administration and inflammatory conditions potentially alter the activity of cytochrome P450 (CYP) 3A4 by modulating the interleukin-6 (IL-6) signaling pathway in patients with rheumatoid arthritis (RA). This study aimed to evaluate the correlations of serum levels of tocilizumab with IL-6 and CYP3A activity in RA.
Methods
RA patients (n = 35) with controllable disease activity using intravenous or subcutaneous tocilizumab were enrolled. Serum tocilizumab was monitored at the trough point after reaching steady-state. Serum levels of IL-6, its soluble receptor (sIL-6R), 4β-hydroxycholesterol (4β-OHC), and 25-hydroxyvitamin D (25-OHD) and CYP3A5 genotype were determined.
Results
The RA patients had a wide variation of serum tocilizumab level (interquartile range, 9.8–24.6 µg/mL). Tocilizumab treatment led to abnormally high levels of serum IL-6 and sIL-6R. The serum level of tocilizumab was correlated with that of IL-6 but not sIL-6R. In the tocilizumab-treated RA patients, the median serum levels of 4β-OHC and 25-OHD were 36.7 and 17.7 ng/mL, respectively, and no correlations with the serum level of tocilizumab were observed. CYP3A5 genetic polymorphisms were not also associated with the serum level of 4β-OHC. RA patients with the CYP3A5*1 allele exhibited a correlation between serum levels of tocilizumab and 4β-OHC, while those with CYP3A5*3/*3 did not.
Conclusions
Tocilizumab treatment raised the serum IL-6 level in a concentration-dependent manner. In the RA patients with functional CYP3A5 protein, the serum tocilizumab level partially explained the interindividual variation in CYP3A activity.
RoblinXSerre-DebeauvaisFPhelipJM, et al.Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Pharmacol Ther2003; 18(9): 917–925.
2.
WangWLeuJWatsonR, et al.Investigation of the mechanism of therapeutic protein-drug interaction between methotrexate and golimumab, an anti-TNFα monoclonal antibody. AAPS J2018; 20(3): 63.
3.
SchmittCKuhnBZhangX, et al.Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther2011; 89(5): 735–740.
4.
NishimotoN. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol2006; 18(3): 277–281.
5.
HashizumeMTanSLTakanoJ, et al.Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights. Int Rev Immunol2015; 34(3): 265–279.
6.
MiharaMKasutaniKOkazakiM, et al.Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol2005; 5(12): 1731–1740.
7.
NishimotoNTeraoKMimaT, et al.Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood2008; 112(10): 3959–3964.
8.
UchiyamaYYoshidaHKoikeN, et al.Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol2008; 8(11): 1595–1601.
9.
Martínez-JiménezCPJoverRDonatoMT, et al.Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metabol2007; 8(2): 185–194.
10.
ZhuangYde VriesDEXuZ, et al.Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol2015; 55(12): 1386–1394.
11.
LeeEBDaskalakisNXuC, et al.Disease-drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacokinet2017; 56(6): 607–615.
12.
HoshikawaKNaitoTAkutsuS, et al.Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients. Basic Clin Pharmacol Toxicol2020; 126(4): 353–363.
13.
SakaguchiKNaitoTHoshikawaK, et al.Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders. Drug Metabol Pharmacokinet2024; 58: 101027.
14.
WollmannBMSyversenSWLieE, et al.4β-hydroxycholesterol level in patients with rheumatoid arthritis before vs. after initiation of bDMARDs and correlation with inflammatory state. Clin Transl Sci2017; 10(1): 42–49.
15.
Schmiedlin-RenPThummelKEFisherJM, et al. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α,25-dihydroxyvitamin D3. Mol Pharmacol. 1997; 51(5): 741–754.
16.
NaitoTOhshiroJSatoH, et al.Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients. Clin Biochem2019; 69: 8–14.
17.
DiczfalusyUMiuraJRohHK, et al. 4β-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genom. 2008; 18(3): 201–208.
18.
IshidaTNaitoTSatoH, et al.Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain. Drug Metabol Pharmacokinet2016; 31(3): 242–248.
19.
SuzukiYMurayaNFujiokaT, et al.Factors involved in phenoconversion of CYP3A using 4β-hydroxycholesterol in stable kidney transplant recipients. Pharmacol Rep2019; 71(2): 276–281.
20.
MarcantonioEEBallardJGibsonCR, et al.Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatib. J Clin Pharmacol2014; 54(11): 1280–1289.
21.
MochizukiTShibataKNaitoT, et al.LC-MS/MS method for the quantitation of serum tocilizumab in rheumatoid arthritis patients using rapid tryptic digestion without IgG purification. J Pharm Anal2022; 12(6): 852–859.
22.
NakatsugawaENaitoTShibataK, et al.Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics. Fundam Clin Pharmacol2024; 38(3): 596–605.
23.
OgataATanimuraKSugimotoT, et al.Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res2014; 66(3): 344–354.
24.
OhtaSTsuruTTeraoK, et al.Optimal dose prediction by pharmacokinetic and biomarker response of subcutaneous tocilizumab treatment a Phase I/II study evaluating the safety, pharmacokinetics and clinical response in patients with rheumatoid arthritis. Arthritis Rheum2010; 62(Suppl 10): S467–468.
25.
ShimamotoKItoTOzakiY, et al.Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol2013; 40(7): 1074–1081.
26.
WangJDevenportJLowJM, et al.Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res2016; 68(6): 882–885.
27.
PortierMLeesDCaronE, et al.Up-regulation of interleukin (IL)-6 receptor gene expression in vitro and in vivo in IL-6 deprived myeloma cells. FEBS Lett1992; 302(1): 35–38.
28.
Diaz-TorneCOrtizMDAMoyaP, et al.The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. Semin Arthritis Rheum2018; 47(6): 757–764.
29.
NaitoTKubonoNIshidaT, et al.CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine. Drug Metabol Pharmacokinet2015; 30(6): 419–424.
30.
DiczfalusyUKanebrattKPBredbergE, et al. 4β-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol. 2009; 67(1): 38–43.
31.
DunvaldACDSøltoftKSheetalE, et al.Cytochrome P450 activity in rheumatoid arthritis patients during continuous IL-6 receptor antagonist therapy. Eur J Clin Pharmacol2023; 79: 1687–1698.
32.
LeviMGrangeSFreyN. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis. J Clin Pharmacol2013; 53(2): 151–159.
33.
TaguchiRNaitoTKubonoN, et al.Relationships between endogenous CYP3A markers and plasma amlodipine exposure and metabolism in early postpartum and non-peripartum women with hypertension. Pregnancy Hypertens2019; 17: 209–215.
34.
HoleKGjestadCHeitmannKM, et al.Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. Eur J Clin Pharmacol2017; 73: 317–324.
35.
Tremblay-FrancoMZerbinatiCPacelliA, et al.Effect of obesity and metabolic syndrome on plasma oxysterols and fatty acids in human. Steroids2015; 99: 287–292.
36.
PenzakSRRojas-FernandezC. 4β-hydroxycholesterol as an endogenous biomarker for CYP3A activity: literature review and critical evaluation. J Clin Pharmacol2019; 59(5): 611–624.
37.
GravelSChiassonJLGaudetteF, et al.Use of 4β-hydroxycholesterol plasma concentrations as an endogenous biomarker of CYP3A activity: clinical validation in individuals with type 2 diabetes. Clin Pharmacol Ther2019; 106(4): 831–840.
38.
HiratsukaMTakekumaYEndoN, et al.Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol2002; 58: 417–421.
39.
EnokiyaTNishikawaKHamadaY, et al.Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: effect of interleukin 6-induced suppression of the cytochrome P450 3A gene. Basic Clin Pharmacol Toxicol2021; 128(3): 525–533.
40.
ThirumaranRKLambaJKKimRB, et al.Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol2012; 84(1): 104–112.
41.
HewisonM. An update on vitamin D and human immunity. Clin Endocrinol2012; 76(3): 315–325.
42.
MateenSMoinSShahzadS, et al.Level of inflammatory cytokines in rheumatoid arthritis patients: correlation with 25-hydroxy vitamin D and reactive oxygen species. PLoS One2017; 12(6): e0178879.
43.
ShobenABKestenbaumBLevinG, et al.Seasonal variation in 25-hydroxyvitamin D concentrations in the cardiovascular health study. Am J Epidemiol2011; 174(12): 1363–1372.
